On page 4, please delete the paragraph encompassing lines 10-16 and insert the following new paragraph:

A3

WO 95/18097 discloses an anthranilic acid derivative represented by the following formula, which inhibits a cyclic GMP phosphodiesterase. In the formula, R_1 to R_4 represent H, a halogen atom, ..., pyrazolyl which may be substituted, ...; n is 0 to 6, W represents N or CH, Y represents O or S, ... (see said published patent application for details).

On page 4, please delete the partial paragraph encompassing lines 17-20 and insert the following new partial paragraph:

A4

An unexamined published Japanese patent application 9-59236 discloses an R^1, R^2-di-substituted benzamide derivative represented by the following formula, which is useful for the prevention and treatment of rheumatic,

On page 8, please delete the paragraph encompassing lines 19-29 and insert the following new paragraph:

A5

The invention also relates to a pharmaceutical composition, particularly a pharmaceutical composition for use in the inhibition of calcium release activated calcium channel, which comprises a pyrazole derivative represented by the following general formula (I') or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. Preferably, it relates to an IL-2 production inhibitor, a preventive or therapeutic agent for allergic, inflammatory or autoimmune diseases and a preventive or therapeutic agent for bronchial asthma or rheumatoid arthritis.

On page 20, please delete the partial paragraph encompassing lines 1-11 and insert the following new partial paragraph:

A6

carboxylic acid or a reactive derivative thereof, and examples of the reactive derivative include acid halides such as acid chlorides, acid bromides and the like; acid azides; active esters which can be prepared using methanol, ethanol, benzyl alcohol, phenol which may be substituted, 1-hydroxybenzotriazole, N-hydroxysuccinimide and the like; symmetric acid anhydrides; and mixed acid anhydrides with alkylcarboxylic acid, p-toluenesulfonic acid and the like. These reactive derivatives are commercially available or can be produced by the usual procedures.

On page 28, please delete the paragraph encompassing lines 3-8 and insert the following new paragraph:

A7

In particular, the compound of the present invention which is possessed of CRACC selective inhibitory activity over VOCC is useful, because it can cause CRACC inhibition without VOCC inhibition-induced undesirable reactions in central nervous system and cardiovascular system and the like.

On page 32, please delete the paragraph encompassing lines 6-13 and insert the following new paragraph:

A8

In four-week-old male BN rats (Charles River, Japan), inhibitory effect on antigen-induced airway eosinophilia was tested in almost the same manner as the method reported by W. Elwood *et al.* in *Inflamm. Res.*, 44: 83-86 (1995). In this connection, the drug was administered 30 minutes before the antigen exposure in the case of intravenous injection or 1 hour before and 3 hours after the antigen exposure in the case of oral administration.